Drug-Induced Liver Injury: Pattern Recognition and Future Directions

키워드

참고문헌 (107)

1. Ostapowicz G, "Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States", Ann Intern Med, 137, pp.947~954 (2002)
2. Wilke RA, "Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges", Nat Rev Drug Discov, 6, pp.904~916 (2007)
3. Björnsson ES, "Epidemiology and risk factors for idiosyncratic drug-induced liver injury", Semin Liver Dis, 34, pp.115~122 (2014)
4. Sgro C, "Incidence of drug-induced hepatic injuries: a French population-based study", Hepatology, 36, pp.451~455 (2002)
5. de Abajo FJ, "Acute and clinically relevant drug-induced liver injury: a population based case-control study", Br J Clin Pharmacol, 58, pp.71~80 (2004)
6. Lee WM, "Recognizing drug-induced liver injury: current problems, possible solutions", Toxicol Pathol, 33, pp.155~164 (2005)
7. Björnsson ES, "Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland", Gastroenterology, 144(e3), pp.1419~1425 (2013)
8. Fountain FF, "Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic", Chest, 128, pp.116~123 (2005)
9. Olsson R, "Liver damage from flucloxacillin, cloxacillin and dicloxacillin", J Hepatol, 15, pp.154~161 (1992)
10. Stock JG, "Unexplained hepatitis following halothane", Anesthesiology, 63, pp.424~439 (1985)
11. Lucena MI, "Determinants of the clinical expression of amoxicillin-clavulanate hepatotoxicity: a prospective series from Spain", Hepatology, 44, pp.850~856 (2006)
12. Stricker BH, "Hepatic injury associated with the use of nitrofurans: a clinicopathological study of 52 reported cases", Hepatology, 8, pp.599~606 (1988)
13. Chalasani N, "Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States", Gastroenterology, 135(e4), pp.1924~1934 (2008)
14. Chalasani NP, "ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury", Am J Gastroenterol, 109, pp.950~966 (2014)
15. Morgan DJ, "Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease: an update", Clin Pharmacokinet, 29, pp.370~391 (1995)
16. Lewis JH, "Review article: prescribing medications in patients with cirrhosis. A practical guide", Aliment Pharmacol Ther, 37, pp.1132~1156 (2013)
17. Saukkonen JJ, "An official ATS statement: hepatotoxicity of antituberculosis therapy", Am J Respir Crit Care Med, 174, pp.935~952 (2006)
18. Sulkowski MS, "Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections", Hepatology, 35, pp.182~189 (2002)
19. Russo MW, "Liver transplantation for acute liver failure from drug induced liver injury in the United States", Liver Transpl, 10, pp.1018~1023 (2004)
20. Lucena MI, "Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex", Hepatology, 49, pp.2001~2009 (2009)
21. Chen M, "High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury", Hepatology, 58, pp.388~396 (2013)
22. Bénichou C, "Criteria of drug-induced liver disorders: report of an international consensus meeting", J Hepatol, 11, pp.272~276 (1990)
23. Benichou C, "Causality assessment of adverse reactions to drugs: II. an original model for validation of drug causality assessment methods: case reports with positive rechallenge", J Clin Epidemiol, 46, pp.1331~1336 (1993)
24. Chitturi S, "Schiff’s diseases of the liver", pp.703~783 (2012), Wiley-Blackwell
25. Hennes EM, "Simplified criteria for the diagnosis of autoimmune hepatitis", Hepatology, 48, pp.169~176 (2008)
26. Czaja AJ, "Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: therapeutic brinksmanship and the point beyond salvation", Liver Transpl, 13, pp.953~955 (2007)
27. Ichai P, "Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis", Liver Transpl, 13, pp.996~1003 (2007)
28. Danan G, "Causality assessment of adverse reactions to drugs: I. a novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries", J Clin Epidemiol, 46, pp.1323~1330 (1993)
29. Maria VA, "Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis", Hepatology, 26, pp.664~669 (1997)
30. Hayashi PH, "Clinical features, diagnosis, and natural history of drug-induced liver injury", Semin Liver Dis, 34, pp.134~144 (2014)
31. Rochon J, "Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury", Hepatology, 48, pp.1175~1183 (2008)
32. Hoofnagle JH, "LiverTox: a website on drug-induced liver injury", Hepatology, 57, pp.873~874 (2013)
33. "LiverTox" (2015)[URL]
34. Temple R, "Hy’s law: predicting serious hepatotoxicity", Pharmacoepidemiol Drug Saf, 15, pp.241~243 (2006)
35. Björnsson E, "Outcome and prognostic markers in severe drug-induced liver disease", Hepatology, 42, pp.481~489 (2005)
36. Andrade RJ, "Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period", Gastroenterology, 129, pp.512~521 (2005)
37. Bahirwani R, "Drug-induced liver injury due to cancer chemotherapeutic agents", Semin Liver Dis, 34, pp.162~171 (2014)
38. Hicks LA, "U.S. outpatient antibiotic prescribing, 2010", N Engl J Med, 368, pp.1461~1462 (2013)
39. Larrey D, "Hepatitis associated with amoxycillin-clavulanic acid combination report of 15 cases", Gut, 33, pp.368~371 (1992)
40. García Rodríguez LA, "Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid", Arch Intern Med, 156, pp.1327~1332 (1996)
41. Reddy KR, "Amoxicillin-clavulanate potassium-associated cholestasis", Gastroenterology, 96, pp.1135~1141 (1989)
42. Richardet JP, "Prolonged cholestasis with ductopenia after administration of amoxicillin", clavulanic acid, 1999, pp.44, 1997~2000
43. Eckstein RP, "Flucloxacillin induced liver disease: histopathological findings at biopsy and autopsy", Pathology, 25, pp.223~228 (1993)
44. Peker E, "Ceftriaxone-induced toxic hepatitis", World J Gastroenterol, 15, pp.2669~2671 (2009)
45. Metushi IG, "A fresh look at the mechanism of isoniazid-induced hepatotoxicity", Clin Pharmacol Ther, 89, pp.911~914 (2011)
46. Tostmann A, "Antituberculosis drug-induced hepatotoxicity: concise up-to-date review", J Gastroenterol Hepatol, 23, pp.192~202 (2008)
47. Sharma SK, "Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity", Clin Infect Dis, 50, pp.833~839 (2010)
48. Tahaoğlu K, "The management of anti-tuberculosis drug-induced hepatotoxicity", Int J Tuberc Lung Dis, 5, pp.65~69 (2001)
49. Durand F, "Deleterious influence of pyrazinamide on the outcome of patients with fulminant or subfulminant liver failure during antituberculous treatment including isoniazid", Hepatology, 21, pp.929~932 (1995)
50. Mainra RR, "Trimethoprim-sulfamethoxazole-associated hepatotoxicity: part of a hypersensitivity syndrome", Can J Clin Pharmacol, 10, pp.175~178 (2003)
51. Yao F, "Trimethoprim-sulfamethoxazole-induced vanishing bile duct syndrome", Am J Gastroenterol, 92, pp.167~169 (1997)
52. García Rodríguez LA, "A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs", Br J Clin Pharmacol, 48, pp.847~852 (1999)
53. Stricker BH, "Ketoconazole-associated hepatic injury: a clinicopathological study of 55 cases", J Hepatol, 3, pp.399~406 (1986)
54. Ikemoto H, "A clinical study of fluconazole for the treatment of deep mycoses", Diagn Microbiol Infect Dis, 12(4), pp.239S~247S (1989)
55. Fischer MA, "The hepatotoxicity of antifungal medications in bone marrow transplant recipients", Clin Infect Dis, 41, pp.301~307 (2005)
56. Núñez M, "Clinical syndromes and consequences of antiretroviral-related hepatotoxicity", Hepatology, 52, pp.1143~1155 (2010)
57. Surgers L, "Hepatoxicity of new antiretrovirals: a systematic review", Clin Res Hepatol Gastroenterol, 37, pp.126~133 (2013)
58. Sulkowski MS, "Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir", AIDS, 18, pp.2277~2284 (2004)
59. Sulkowski MS, "Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors", Clin Infect Dis, 38(2), pp.S90~S97 (2004)
60. Eshki M, "Twelve-year analysis of severe cases of drug reaction with eosinophilia and systemic symptoms: a cause of unpredictable multiorgan failure", Arch Dermatol, 145, pp.67~72 (2009)
61. Mullick FG, "Hepatic injury associated with diphenylhydantoin therapy: a clinicopathologic study of 20 cases", Am J Clin Pathol, 74, pp.442~452 (1980)
62. Zimmerman HJ, "Valproate-induced hepatic injury: analyses of 23 fatal cases", Hepatology, 2, pp.591~597 (1982)
63. Lacroix I, "Nonsteroidal anti-inflammatory drug-induced liver injury: a case-control study in primary care", Fundam Clin Pharmacol, 18, pp.201~206 (2004)
64. Johnson AG, "The problems and pitfalls of NSAID therapy in the elderly (Part I)", Drugs Aging, 1, pp.130~143 (1991)
65. Manoukian AV, "Nonsteroidal anti-inflammatory drug-induced hepatic disorders: incidence and prevention", Drug Saf, 15, pp.64~71 (1996)
66. Riley TR 3rd, "Ibuprofen-induced hepatotoxicity in patients with chronic hepatitis C: a case series", Am J Gastroenterol, 93, pp.1563~1565 (1998)
67. Andrade RJ, "Chronic hepatitis C, ibuprofen, and liver damage", Am J Gastroenterol, 97, pp.1854~1855 (2002)
68. Scully LJ, "Diclofenac induced hepatitis: 3 cases with features of autoimmune chronic active hepatitis", Dig Dis Sci, 38, pp.744~751 (1993)
69. Daly AK, "Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes", Gastroenterology, 132, pp.272~281 (2007)
70. Maddrey WC, "The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib", Am J Ther, 7, pp.153~158 (2000)
71. El Hajj I, "Celecoxib-induced cholestatic liver failure requiring orthotopic liver transplantation", World J Gastroenterol, 15, pp.3937~3939 (2009)
72. Tolman KG, "Defining patient risks from expanded preventive therapies", Am J Cardiol, 85, pp.15E~19E (2000)
73. McKenney JM, "National Lipid Association Statin Safety Assessment Task Force. Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force", Am J Cardiol, 97, pp.89C~94C (2006)
74. Lewis JH, "Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial", Hepatology, 46, pp.1453~1463 (2007)
75. Avins AL, "Hepatic effects of lovastatin exposure in patients with liver disease: a retrospective cohort study", Drug Saf, 31, pp.325~334 (2008)
76. Grimbert S, "Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin", Dig Dis Sci, 39, pp.2032~2033 (1994)
77. Hartleb M, "Acute cholestatic hepatitis associated with pravastatin", Am J Gastroenterol, 94, pp.1388~1390 (1999)
78. Pelli N, "Autoimmune hepatitis revealed by atorvastatin", Eur J Gastroenterol Hepatol, 15, pp.921~924 (2003)
79. Tolman KG, "The liver and lovastatin", Am J Cardiol, 89, pp.1374~1380 (2002)
80. Di Bisceglie AM, "Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg?", Hepatology, 61, pp.703~711 (2015)
81. Lok AS, "Chronic hepatitis B: update 2009", Hepatology, 50, pp.661~662 (2009)
82. Ghabril M, "Liver injury from tumor necrosis factor-alpha antagonists: analysis of thirty-four cases", Clin Gastroenterol Hepatol, 11(e3), pp.558~564 (2013)
83. Becker H, "Etanercept tolerance in a patient with previous infliximab-induced hepatitis", Clin Rheumatol, 27, pp.1597~1598 (2008)
84. Thiéfin G, "Infliximab-induced hepatitis: absence of cross-toxicity with etanercept", Joint Bone Spine, 75, pp.737~739 (2008)
85. Parekh R, "Liver injury secondary to anti-TNF-alpha therapy in inflammatory bowel disease: a case series and review of the literature", Case Rep Gastrointest Med, 2014, pp.956463~ (2014)
86. Bailey RL, "Dietary supplement use in the United States, 2003-2006", J Nutr, 141, pp.261~266 (2011)
87. Navarro VJ, "Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network", Hepatology, 60, pp.1399~1408 (2014)
88. Navarro VJ, "Hepatotoxicity induced by herbal and dietary supplements", Semin Liver Dis, 34, pp.172~193 (2014)
89. Bunchorntavakul C, "Review article: herbal and dietary supplement hepatotoxicity", Aliment Pharmacol Ther, 37, pp.3~17 (2013)
90. Skoulidis F, "Ma huang associated acute liver failure requiring liver transplantation", Eur J Gastroenterol Hepatol, 17, pp.581~584 (2005)
91. Neff GW, "Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid", J Hepatol, 41, pp.1062~1064 (2004)
92. "FDA issues regulation prohibiting sale of dietary supplements containing ephedrine alkaloids and reiterates its advice that consumers stop using these products" (2004)[URL]
93. Navarro VJ, "Catechins in dietary supplements and hepatotoxicity", Dig Dis Sci, 58, pp.2682~2690 (2013)
94. Bonkovsky HL, "Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis)", Ann Intern Med, 144, pp.68~71 (2006)
95. Javaid A, "Hepatotoxicity due to extracts of Chinese green tea (Camellia sinensis): a growing concern", J Hepatol, 45, pp.334~335 (2006)
96. Vanstraelen S, "Jaundice as a misadventure of a green tea (camellia sinensis) lover: a case report", Acta Gastroenterol Belg, pp.409~412 (2008)
97. Dara L, "Hydroxycut hepatotoxicity: a case series and review of liver toxicity from herbal weight loss supplements", World J Gastroenterol, 14, pp.6999~7004 (2008)
98. Singh V, "Severe hepatotoxicity caused by a methasteron-containing performance-enhancing supplement", J Clin Gastroenterol, 43, pp.287~ (2009)
99. Martin DJ, "Hepatotoxicity associated with the dietary supplement N.O.-XPLODE", Ann Intern Med, 159, pp.503~504 (2013)
100. Glober GA, "Biliary cirrhosis following the administration of methyltestosterone", JAMA, 204, pp.170~173 (1968)
101. Westaby D, "Androgen related primary hepatic tumors in non-Fanconi patients", Cancer, 51, pp.1947~1952 (1983)
102. Monshi MM, "Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury", Hepatology, 57, pp.727~739 (2013)
103. Chung WH, "Medical genetics: a marker for Stevens-Johnson syndrome", Nature, 428, pp.486~ (2004)
104. Sharma SK, "Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment", Am J Respir Crit Care Med, 166, pp.916~919 (2002)
105. Martin AM, "Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts", AIDS, 19, pp.97~99 (2005)
106. Urban TJ, "Genetic basis of drug-induced liver injury: present and future", Semin Liver Dis, 34, pp.123~133 (2014)
107. Bamshad MJ, "Exome sequencing as a tool for Mendelian disease gene discovery", Nat Rev Genet, 12, pp.745~755 (2011)

관련 논문AI추천